GlassScriptPhysician profile
Stephen O Davis
NPI 1801850102
$721.95
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $101 · 2021: $142 · 2022: $92.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.55 | 2019-2021 | |
| Janssen Biotech, INC. | $174.90 | 2019-2022 | |
| Abbvie INC. | $115.97 | 2019-2021 | |
| Pfizer INC. | $64.31 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $32.39 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $23.81 | 2020 | |
| Shionogi INC | $20.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.57 | 2019 | |
| Shire North American Group INC | $17.19 | 2019 | |
| Braintree Laboratories, INC. | $15.35 | 2019 | |
| Allergan, INC. | $12.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.